MS Therapeutics Market to Reach $66.8 Billion by 2035 as Asia-Pacific Grows 10.8%
Updated
Updated · Precedence Research · May 27
MS Therapeutics Market to Reach $66.8 Billion by 2035 as Asia-Pacific Grows 10.8%
1 articles · Updated · Precedence Research · May 27
$37.16 billion in 2026 market size is projected to expand to $66.80 billion by 2035, implying a 6.9% CAGR for multiple sclerosis therapeutics.
Rising MS diagnoses, wider use of biologics and newer disease-modifying treatments are driving growth, while AI tools are increasingly used in diagnosis, MRI analysis, drug discovery and patient monitoring.
Monoclonal antibodies led drug classes with a 32% share in 2025 and are forecast to grow fastest at 10.5%, while oral therapies held a 44% administration share and online pharmacies are set to expand at 11.8%.
North America held 42% of the market in 2025, but Asia-Pacific is expected to post the fastest regional growth at 10.8% as healthcare spending, neurology infrastructure and access to advanced therapies improve.
As the MS drug market booms, why are life-changing treatments still out of reach for so many patients?
With AI now predicting MS, who ensures the technology is a tool for healing and not for discrimination?
Why is a breakthrough MS drug deemed safe for Europe but rejected as too risky for Americans by the FDA?